ALLO-501A-202: A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)

Objective

Clinical Trial Details

Clinical Trial Categories

  • Lymphoma
Contact
Hematology Research Coordinators at 605-322-3090
or hematologyresearch@avera.org

Location

  • Avera Cancer Institute — Mitchell
    605 N Foster St
    Mitchell, SD 57301
    Main: 605-995-5756
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000